Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol

Adolescents ALL have a better outcome when treated with pediatric protocol compared to adult protocol. We have tested the feasibility of pediatric protocol to treat 40 consecutive adults ALL. DFS and OS were 73 ± 7%, and 72 ± 7%, and were significantly longer in patients under 40 yo (81 ± 9% vs 51 ± 15%, p = 0.05 [DFS] and 83 ± 7.8% vs 45 ± 15%, p = 0.003 [OS], respectively) or cortico/chemo-sensitive (86 ± 9% vs 36 ± 16%, p = 0.001 [DFS] and 95 ± 4.4% vs 28 ± 13%, p < 0.0001 [OS]) than in other patients. Overall tolerance was acceptable. We have shown the feasibility of using this unmodified pediatric protocol to treat adult with ALL up to 40 years.